Regular and Young Investigator Award Abstracts 2020
DOI: 10.1136/jitc-2020-sitc2020.0632
|View full text |Cite
|
Sign up to set email alerts
|

632 HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors

Abstract: BackgroundEpithelial cell adhesion molecule (EpCAM) is highly expressed in many solid tumors. However, therapeutics targeting EpCAM have had limited clinical utility or failed in clinical development likely due to the expression of EpCAM in normal tissues. For example, clinical testing of solitomab, an EpCAM-targeting T cell engager, resulted in severe dose-limiting toxicities, including elevated liver transaminases, hyperbilirubinemia, and diarrhea. Designing an EpCAM-targeting T cell engager that is only act… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 1 publication
0
1
0
Order By: Relevance
“…Building on the concept of spatial control, conditional BsAbs are engineered to only become active once conditions associated with the tumor are met, for example, by including a peptide mask that is cleaved by tumor proteases or by requiring the presence of two antigens for unmasking and dimerization of the CD3 binding domain [ 141 , 142 , 143 , 144 , 145 , 146 , 147 ]. These platforms are yet to be tested in GBM but would likely be applicable, especially if designed for activation in a hypoxic TME, for example.…”
Section: Bispecific Antibodiesmentioning
confidence: 99%
“…Building on the concept of spatial control, conditional BsAbs are engineered to only become active once conditions associated with the tumor are met, for example, by including a peptide mask that is cleaved by tumor proteases or by requiring the presence of two antigens for unmasking and dimerization of the CD3 binding domain [ 141 , 142 , 143 , 144 , 145 , 146 , 147 ]. These platforms are yet to be tested in GBM but would likely be applicable, especially if designed for activation in a hypoxic TME, for example.…”
Section: Bispecific Antibodiesmentioning
confidence: 99%